The most common MET-activating alterations in newly diagnosed non-squamous NSCLC are gene amplification (described in 2% to 5% of cases, depending on the different scoring systems adopted in clinical studies) and MET exon 14 (METex14) skipping mutations (occurring in 2% to 4% of cases) [17,18,19,20,21]. Here, MET is linked to non-small cell lung carcinoma.